TSXV:HEM - Post Discussion
Post by
DanielOTC on Jul 06, 2022 6:53am
Creating Personalized Regenerative Cell Therapies
Hemostemix’s technology uses a patient’s own cells to treat that patient’s disease. The cornerstone of this autologous technology is a novel cell population within the blood called the synergetic cell population (SCP). The synergetic cell population, which can be collected from a simple blood draw, consists of progenitor and other supporting cells that are being developed for the treatment of ischemic diseases.
Hemostemix’s proprietary technology includes methods for collecting the synergetic cell population and manufacturing (isolation, enrichment and differentiation) a personalized regenerative therapy that can be administered to a patient within 7 days of the initial cell collection.
[url=https://www.otcmarkets.com/stock/HMTXF/overview][/url]
Be the first to comment on this post